The Drug Information Association (DIA) India is organizing its flagship
PV conference “PV –Fast Forward”-Technology, Pace and Priority. The
event will be held on March 24 and 25, 2017 at the Hotel The Lalit,
Mumbai.
The two-day event will have Moin Don, CEO and President,
PVCON as The Chair and Krishna Bahadur Singh, senior vice president,
safety& risk management, business unit, ARIS Global LLC &
Representative Director, AGKK, Tokyo, Japan as the vice chair.
Programme
will highlight Label Management & Risk Management, Automation in
PV, Compliance Management in PV, Latest Regulations in PV, advanced
Technologies to Handle Safety Data, delve on the importance of
technology in bringing about higher patient safety.
At the end of
the conference, the participants should be able to comprehend multiple
facets of global drug safety concepts along with insights on Indian
Pharmacovigilance, understand how new technologies can help in improving
adverse event reporting and processing of safety data. In addition,
they will be able to discuss the advancements in pharmacovigilance in
the European Union and how it influences the global drug safety, stated
Manoj Trivedi, senior manager, business development, DIA (India) Private
Limited.
According to the organisers, technological advancements
are rapidly impacting the way pharmacovigilance obligations will be
fulfilled by marketing authorization holders. The modus operandi of
conducting pharmacovigilance operations is expected to change
significantly by the year 2020. Automation, artificial intelligence,
machine learning, cognitive computing, proactive pharmacovigilance are
shaping the new paradigm of the safety world.
“Achieving
compliance at a lower cost and higher quality is much closer as a goal
today than it was ever before. Therefore PV fast forward is a meeting of
minds provides an opportunity to cross learn. The conference will
ensure enough opportunity to interact with speakers and colleagues from
the entire spectrum of the pharmacovigilance domain in India,” said the
organisers.
Programme Committee comprises Achint Kumar Gupta, EU
QPPV, Safety & Benefit-Risk Management, Biogen, Jamal Anwar Baig,
Country Head, Pharmacovigilance, Merck Sharp & Dohme, J Vijay
Venkataraman, managing director & CEO, Oviya MedSafe, Mangesh
Kulkarni, headp Pharmacovigilance, TCS, Rajesh Jain, director operations
& business solutions, Cognizant, Retesh Kumar, senior business
consultant and Engagement Lead, Tata Consultancy Services G
Parthasarathi, Dean, Faculty of Pharmacy, JSS University, Vivek Ahuja,
VP Global , Pharmacovigilance, ArisGlobal.
|